Volume 26, Number 4—April 2020
Synopsis
Decreased Susceptibility to Azithromycin in Clinical Shigella Isolates Associated with HIV and Sexually Transmitted Bacterial Diseases, Minnesota, USA, 2012–2015
Table 4
Disease | DSA, n = 42, no. (%) | Azithromycin susceptible, n = 175, no. (%) | OR (95% CI)† | p value |
---|---|---|---|---|
Chlamydia | 13 (31) | 9 (5) | 8.3 (3.2–21.1) | <0.001 |
Gonorrhea | 10 (24) | 10 (6) | 5.2 (2.0–13.4) | 0.001 |
Syphilis | 5 (12) | 2 (1) | 11.7 (2.2–62.6) | 0.003 |
HIV‡ | 25 (60) | 40 (23) | 5.0 (2.4–10.1) | <0.001 |
Any bacterial STD§ | 20 (48) | 16 (9) | 9.0 (4.1–20.0) | <0.001 |
Multiple bacterial STDs§ | 9 (21) | 5 (3) | 9.3 (2.9–29.4) | <0.001 |
*All Shigella infections reported in men are included. Two men who were PLWH had 2 Shigella infections, and 1 man who was PLWH had 3 Shigella infections during the study period. DSA, decreased susceptibility to azithromycin; OR, odds ratio; PLWH, persons living with HIV; STD, sexually transmitted disease.
†Reference group is men with azithromycin-susceptible Shigella.
‡HIV positive at any time before Shigella isolation.
§Chlamydia, gonorrhea, or syphilis only.
Page created: March 17, 2020
Page updated: March 17, 2020
Page reviewed: March 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.